240 related articles for article (PubMed ID: 30762670)
41. Novel therapeutic approaches for recurrent nonmuscle invasive bladder cancer.
Boehm BE; Svatek RS
Urol Clin North Am; 2015 May; 42(2):159-68, vii. PubMed ID: 25882558
[TBL] [Abstract][Full Text] [Related]
42. Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?
Yuk HD; Jeong CW; Kwak C; Kim HH; Ku JH
PLoS One; 2018; 13(11):e0208267. PubMed ID: 30496283
[TBL] [Abstract][Full Text] [Related]
43. Developments in intravesical therapy for non-muscle-invasive bladder cancer.
Lammers RJ; Witjes JA
Expert Rev Anticancer Ther; 2010 Dec; 10(12):1903-16. PubMed ID: 21110757
[TBL] [Abstract][Full Text] [Related]
44. What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence.
Abufaraj M; Mostafid H; Shariat SF; Babjuk M
Curr Opin Urol; 2018 Nov; 28(6):570-576. PubMed ID: 30138122
[TBL] [Abstract][Full Text] [Related]
45. [Treatment of Bacillus Calmette-Guerin refractory superficial bladder cancer: further intravesical therapy].
Kohjimoto Y; Iba A; Shintani Y; Uekado Y; Shinka T
Hinyokika Kiyo; 2005 Aug; 51(8):533-8. PubMed ID: 16164269
[TBL] [Abstract][Full Text] [Related]
46. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
[TBL] [Abstract][Full Text] [Related]
47. Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?
Sari Motlagh R; Pradere B; Mori K; Miura N; Abufaraj M; Shariat SF
Curr Opin Urol; 2020 Jul; 30(4):584-593. PubMed ID: 32304379
[TBL] [Abstract][Full Text] [Related]
48. How to Treat Multifocal Ta High-grade Disease if Bacillus Calmette-Guérin Is Unavailable.
Witjes JA; Brausi M; Malmstrom PU
Eur Urol Oncol; 2020 Oct; 3(5):705-709. PubMed ID: 31324506
[TBL] [Abstract][Full Text] [Related]
49. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
50. Bladder cancer: current optimal intravesical treatment.
Lamm DL; McGee WR; Hale K
Urol Nurs; 2005 Oct; 25(5):323-6, 331-2. PubMed ID: 16294610
[TBL] [Abstract][Full Text] [Related]
51. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
Lamm D; Brausi M; O'Donnell MA; Witjes JA
Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
[TBL] [Abstract][Full Text] [Related]
52. Salvage Therapies for Non-muscle-invasive Bladder Cancer: Who Will Respond to Bacillus Calmette-Guérin? Predictors and Nomograms.
Faba ÓR; Pisano F; Krajewski W; Breda A; Palou J
Urol Clin North Am; 2020 Feb; 47(1):5-13. PubMed ID: 31757300
[TBL] [Abstract][Full Text] [Related]
53. Intravesical combination therapies for non-muscle invasive bladder cancer: Recent advances and future directions.
Li Y; Youssef SF; Buanz AB
Eur J Pharmacol; 2022 Jul; 926():175024. PubMed ID: 35580708
[TBL] [Abstract][Full Text] [Related]
54. Investigational therapies for non-muscle invasive bladder cancer.
Smaldone MC; Casella DP; Welchons DR; Gingrich JR
Expert Opin Investig Drugs; 2010 Mar; 19(3):371-83. PubMed ID: 20078248
[TBL] [Abstract][Full Text] [Related]
55. Real-world efficacy of adjuvant single-agent intravesical gemcitabine for non-muscle invasive bladder cancer.
Abou Chakra M; Packiam VT; O'Donnell MA
Expert Opin Pharmacother; 2023; 24(18):2081-2091. PubMed ID: 37842956
[TBL] [Abstract][Full Text] [Related]
56. [Recurrent bladder cancer after BCG instillation therapy. Local therapy options?].
Laturnus JM; Jocham D; Sommerauer M
Urologe A; 2012 Sep; 51(9):1209-19. PubMed ID: 22580923
[TBL] [Abstract][Full Text] [Related]
57. Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer.
Chevuru PT; McElree IM; Mott SL; Steinberg RL; O'Donnell MA; Packiam VT
Urol Oncol; 2023 Mar; 41(3):148.e1-148.e7. PubMed ID: 36456454
[TBL] [Abstract][Full Text] [Related]
58. Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer.
Crijnen J; De Reijke TM
Expert Opin Emerg Drugs; 2018 Jun; 23(2):135-147. PubMed ID: 29730950
[TBL] [Abstract][Full Text] [Related]
59. Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.
Meng MV; Gschwend JE; Shore N; Grossfeld GD; Mostafid H; Black PC
J Urol; 2019 Dec; 202(6):1111-1119. PubMed ID: 31042108
[TBL] [Abstract][Full Text] [Related]
60. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment].
Higashi S; Matsui Y; Takahashi T; Nishiyama H; Ito N; Yamamoto S; Kamoto T; Ogawa O
Hinyokika Kiyo; 2005 Aug; 51(8):529-31. PubMed ID: 16164268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]